ZURA
$6.44
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist a...
Recent News
UniFirst, Elastic NV, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar